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ABSTRACT The choice of transmitter made by post-
mitotic rat sympathetic neurons in cell culture can be controlled
by the environment in which they develop. One of the differ-
entiation signals is a protein secreted by heart cells that can
induce previously noradrenergic neurons to synthesize acetyl-
choline and form cholinergic synapses. This change in pheno-
type occurs without alteration in neuronal survival or growth.
The differentiation factor has now been purified at least
100,000-fold, and it is homogeneous by several criteria. (t) The
cholinergic activity comigrates with a single 125I-labeled protein
band of 45 kDa in one-dimensional NaDodSO4/PAGE. (it) The
biological activity comigrates precisely with a series of five
'25I-labeled protein spots of 45 kDa in two-dimensional gel
electrophoresis. (i) Treatment of the 45-kDa band with
endo-fi-N-acetylglucosaminidase F reduces the apparent mo-
lecular size of both the labeled protein and the biological
activity to a band of 22 kDa. The data suggest that the
differentiation factor is a slightly basic glycoprotein with at
least six glycosylation sites.
Differentiation of appropriate phenotypes in the developing
vertebrate nervous system involves a high degree of cellular
interaction. Perhaps the most detailed information concern-
ing environmental influences on differentiation involves the
choice of neurotransmitter and synaptic phenotype made by
neural crest derivatives (1-4). In these studies, the decision
under investigation is not whether to differentiate or not, but
rather which of many possible differentiation paths to take.
Single postmitotic rat sympathetic neurons, for instance, can
be made to form noradrenergic, cholinergic, or dual-function
synapses with cardiac myocytes in microcultures (5-7).
Depending on the developmental cues present in vitro, these
neurons also have the capacity to produce several neuropep-
tides (8) and purines (9, 10), and they can be induced to form
electrical synapses (11-13). This plasticity in choice of
transmitter is not simply a reflection of the developmental
potential these neurons possess under artificial conditions,
because at least some of these phenotypic transitions are
actually expressed during normal embryogenesis. That is, the
subpopulation of sympathetic neurons that is cholinergic and
innervates the sweat glands in the rat passes through a
noradrenergic stage before becoming cholinergic (14, 15).
Substitution of one transmitter or neuropeptide phenotype
for another during normal development may also occur in
mammalian enteric, sensory, and parasympathetic ganglia
(16-19); in retina (20); and in identified snail neurons (21).
The culture paradigm offers an opportunity for identifying
and characterizing some of the environmental signals that can
influence these differentiation decisions. In the case of the
sympathoadrenal lineage, a number of such cues have been
identified, including nerve growth factor (22-24), glucocor-
ticoids (22-27), epidermal growth factor (26), insulin (12, 13),
electrical activity and Ca2+ influx (28, 29), rat serum (30), and
nonneuronal cells and their conditioned medium (CM)
(31-34). Such signals have been termed "instructive," in
order to distinguish them from growth factors that have been
termed "permissive" (2). Some developmental cues can act
in either way, however, depending on the circumstances. For
instance, nerve growth factor is permissive for the develop-
ment of both noradrenergic and cholinergic sympathetic
neurons (35), but it can also act instructively by converting
chromaffin cells into neurons (22, 23). Similarly, gluco-
corticoids and insulin are necessary for the survival of certain
cells in the sympathoadrenal lineage, but these hormones can
also influence the choice ofphenotype as well (12, 13, 22-26).
There have been many reports of macromolecules influ-
encing neuronal development, but in most cases it has been
difficult to assess the instructive vs. permissive effects of
these agents on their target neurons. One clear case of a
selective differentiation effect is the release of a factor by
certain nonneuronal cells that can convert noradrenergic
sympathetic neurons to the cholinergic phenotype without
altering survival or growth (31, 32, 34, 36). The same, or a
very similar, factor induces cholinergic properties in sensory
and spinal cord neurons (37, 38) and, possibly, in parasym-
pathetic neurons as well (39). Direct comparison of these
factors depends on purifying and characterizing them. Stud-
ies on their roles in normal development in vivo also require
purification and the generation of appropriate immunological
and molecular probes. Purification of differentiation factors
in CM has proven difficult because of the small amounts of
material available and the long assay time required (2-3
weeks). Progress has been made with the cholinergic factor
that acts on sympathetic neurons, however. Initial charac-
terization of this molecule, obtained from serum-containing
CM, revealed that the activity resides in a Pronase-sensitive
molecule of 45 kDa, as determined by Sephadex chromatog-
raphy (40). Manipulation of the hormonal composition of the
medium enabled me to obtain an active cholinergic prepara-
tion of serum-free CM from neonatal rat heart cells (26). By
using this starting material, an apparently homogeneous
glycoprotein has now been obtained that retains the ability to
both induce cholinergic properties and reduce adrenergic
properties in cultures of dissociated sympathetic neurons
from the neonatal rat superior cervical ganglion. This report
presents the purification protocol and describes some of the
properties of this protein. Preliminary accounts of this work
have appeared previously (41-43).
MATERIALS AND METHODS
[methyl-3H]Choline chloride and L-[2,6-3H]tyrosine were
obtained from New England Nuclear or from Amersham.
N-succinimidyl 3-(4-hydroxy, 5-['25I]iodophenyl)propionate
Abbreviations: AcCho, acetylcholine; CA, catecholamine.
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(125I-Bolton-Hunter reagent) was obtained from Amersham.
Endo-/3-N-acetylglucosaminidase F (endoglycosidase F) was
obtained from New England Nuclear. 1,3,4,6-Tetrachloro-
3a-6a-diphenylglycouril (Iodo-Gen) was from Pierce.
Neuron Cultures. Neuron cultures were prepared as de-
scribed by Hawrot and Patterson (44). The fractions to be
tested for biological activity were kept frozen in sterile
aliquots after dialysis against phosphate-buffered saline. The
fractions were mixed with fresh growth medium (44) and
given to the cultures every other day. Neurotransmitter
production was assayed on day 16-19.
Purification of the Cholinergic Factor. Serum-free hor-
mone-supplemented CM from primary cultures of newborn
rat heart cells was obtained as described (26). The first
purification step was precipitation with ammonium sulfate as
described by Weber (40). All the activity was recovered in the
60-100% precipitate. DEAE and CM-cellulose and Sephadex
column chromatography were performed as described by
Weber (40) with minor modifications. All the activity ran
through DEAE-cellulose columns equilibrated with 5 mM
sodium phosphate, pH 7.0/0.2 mM Na2EGTA (DEAE-
cellulose fraction). The DEAE-cellulose fraction was applied
to a CM-cellulose column and eluted with a gradient of 5-100
mM sodium phosphate, pH 7.0/0.2 mM Na2EGTA/0.01%
polyethylene glycol 6000 (PEG). PEG was included in all
buffers after this stage of purification to prevent loss of the
activity due to nonspecific adsorption. More than 80% of the
activity was recovered as a single peak at 15-40 mM salt
concentration (CM-cellulose fraction). The behavior on these
columns indicates that the cholinergic factor is a slightly basic
molecule. The CM-cellulose fraction was loaded on a Seph-
adex G-100 (Superfine, Pharmacia) column (1.5 x 100 cm) in
5 mM phosphate, pH 7.0/150 mM NaCl/0.2 mM Na2EGTA/
0.01% PEG after concentration on a PM-10 Diaflow mem-
brane (Amicon) and run at a flow rate of =3.5 ml/hr. A single
activity peak was obtained at an apparent molecular size of
-45 kDa (Sephadex fraction). The NaDodSO4/PAGE sys-
tem of Laemmli (45) was used as the final purification step.
The separating gel was 10% polyacrylamide made from a
stock solution of 30% acrylamide and 0.2% N,N'-methylene-
bisacrylamide. The N,N'-methylene-bisacrylamide concen-
tration was lower than that normally used to improve the
elution efficiency. Disulfide reducing agents were not includ-
ed in the sample buffer except where specified, because they
destroy the activity in the presence of NaDodSO4. The
molecular size markers used were myosin (200 kDa), (-
galactosidase (116 kDa), phosphorylase B (94 kDa), bovine
serum albumin (68 kDa), ovalbumin (43 kDa), carbonic
anhydrase (30 kDa), trypsin inhibitor (22 kDa), and lysozyme
(14.3 kDa). Samples from preparative NaDodSO4/PAGE
were tested for biological activity as follows: the gel was
sliced into 2- to 3-mm segments and eluted overnight at 4°C
in 0.05 M Tris acetate, pH 7.8/0.01% PEG/bovine serum
albumin (2 mg/ml). Each eluate was loaded on an AG 1-X2
(Bio-Rad) column equilibrated with 0.05 M Tris acetate, pH
7.8/0.01% PEG to remove NaDodSO4 according to the
method of Weber and Kuter (46). The run-through fraction
was dialyzed against phosphate-buffered saline, sterilized by
filtration, and kept frozen in aliquots until use.
Two-Dimensional Gel Electrophoresis. Nonequilibrium pH
gradient electrophoresis for both basic and acidic proteins
was performed as described by O'Farrell et al. (47) with the
following modifications. Samples were concentrated and
desalted by centrifugation on centricon filters (Amicon).
Urea, Nonidet P-40, and ampholines (LKB) were added to
final concentrations of 9.5 M, 2%, and 2%, respectively, and
loaded as the first-dimension gel (0.25 x 11 cm). Ampholines
(pH 3.5-10) or a mixture containing equal parts of ampholines
at pH 6-8 and pH 5-7 were used. Samples were electropho-
resed, usually for 4-5 hr at 400-500 V, for a total of 2000-3000
V-hr in the first dimension. The first-dimension cylindrical gel
was immediately loaded on the second-dimension slab gel
without equilibration to avoid protein loss, as described by
O'Farrell (48), and it was run as described above. Standards
used were bovine serum albumin (68 kDa; pl, 4.9), ovalbumin
(43 kDa; pI, 4.6), myoglobin (17.5 kDa; pI, 7.0), and
cytochrome c (13.3 kDa; pl, 10.7).
Endoglycosidase F Treatment. Incubations were carried out
for 16 hr at 370C in buffer containing 0.1M sodium phosphate,
pH 6.0/50 mM EDTA/1% Nonidet P-40/0.1% NaDodSO4/1
mM phenylmethylsulfonyl fluoride/0.01% PEG, according to
the conditions recommended by New England Nuclear (49).
The amount of added endoglycosidase F varied from 0 to 20
units, where 1 unit is the amount of enzyme that deglycosyl-
ates 15 Ag of RNase B in 1 hr (New England Nuclear).
2-Mercaptoethanol facilitated deglycosylation by endoglyco-
sidase F (49) but did not increase the apparent number of
cleavage sites for endoglycosidase F. NaDodSO4 was added
to a final concentration of 3% in preparing samples for
NaDodSO4/PAGE.
lodination. lodination of tyrosine residues was performed
by the chloramine-T (50), Iodo-Gen (Pierce), or lacto-
peroxidase (51) method. Iodination according to the
Bolton-Hunter method (52) was performed as follows:
100-200 ,ug of the Sephadex fraction in 0.1 M borate buffer
(pH 8.5) was added to 0.25-0.5 nmol of the dried 1251
Bolton-Hunter reagent and the reaction was allowed to
proceed for 15 min on ice. To inactivate unreacted reagent,
glycine was added to a final concentration of 0.25 M and the
mixture was kept at 4°C until loading on the gel.
Silver Staining. Silver staining of proteins separated by
NaDodSO4/PAGE was done according to the methods of
Merril et al. (53), Irie et al. (54), and Oakley et al. (55). In
these methods, at least 10 ng of ovalbumin was detected as
a standard.
Estimation of Protein. The amount of protein was deter-
mined by the method of Lowry et al. (56), except following
NaDodSO4/PAGE. Since the 45-kDa region, where biolog-
ical activity is located (see below), was not labeled by
silver-staining methods, Bolton-Hunter iodination was used
to estimate the protein content of this area. The 125I-labeled
Sephadex fraction was subjected to 10o NaDodSO4/PAGE
after separation from the 1251-Bolton-Hunter reagent by
Sephadex G-50, equilibrated with phosphate-buffered saline
containing 0.25% gelatin. The percentage of the label in the
45-kDa region was calculated, and the amount of protein was
then estimated by multiplying the percentage by the total
protein in the 1251I-labeled Sephadex fraction applied to the
gel. Alternatively, known amounts of ovalbumin were la-
beled in the same way and analyzed by NaDodSO4/PAGE.
The radioactivity in the ovalbumin band of known protein
concentration was compared to the radioactivity in the
45-kDa region of the Sephadex fraction. Both methods
yielded similar estimates.
RESULTS
Purification of the Factor. The assay for cholinergic activity
involves incubating CM fractions with primary cultures of
dissociated sympathetic neurons for 2-3 weeks, changing the
medium every other-day. At the end of this period, the
cultures are incubated with [3H]tyrosine and [3H]choline
chloride for 4-5 hr, extracted, and the resulting 3H-labeled
catecholamine (CA) and acetylcholine (AcCho) were sepa-
rated by paper electrophoresis and counted. The resulting
data are a measure of net synthesis and accumulation of the
transmitters from their precursors, and they include the
processes of synthesis, storage, and degradation (57). This is
a physiologically relevant measure of how the neurons use
precursors in vivo. Results from such experiments have also
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Table 1. Purification of the cholinergic factor
Specific
Total Total activity, Recovery, Purification,
Fraction protein, mg activity, units units/mg % -fold
CM 44,000 40,340 0.9 100 1
(NH4)2SO4 43,000 26,120 0.6 65 0.7
DEAE-cellulose 142.0 52,850 370 130 410
CM-cellulose 22.0 32,210 1,460 80* 1,620
Sephadex G-100 6.0 30,000 5,000 74 5,560
NaDodSO4/PAGE 0.07 6,430 91,900 16 102,000
Units of activity are expressed as the transmitter ratio, AcCho/CA (32). The amount of protein was determined as
described. Serum-free CM (17.5 liters) was used as the starting material for the results shown here.
*The activity is recovered from the CM-cellulose column as a single broad peak at 15-40 mM salt concentration. However,
only some of these fractions were pooled in order to increase the specific activity. Thus, the recovery of 80%o is an
underestimate.
been shown to correlate very well with the levels of the
biosynthetic enzymes for these transmitters (choline acetyl-
transferase and tyrosine hydroxylase) as determined by
activity assays of homogenates and by immunocytochemical
staining (32, 58). The data are usually expressed as the
increase in the ratio of the two transmitters, AcCho/CA,
caused by a particular concentration ofCM (-fold induction).
While in this laboratory, Weber (40) developed a number
of initial purification steps for the cholinergic factor by using
serum-containing CM. After devising a suitable serum-free
medium based on that of Bottenstein et al. (59), I applied
several of these steps in sequence to achieve a 5560-fold
increase in specific activity with a high recovery (Table 1).
Since the activity is stable to treatment with NaDodSO4
under nonreducing conditions, preparative NaDodSO4/
PAGE was added as a final step. As shown in Fig. 1, the
activity runs as a single peak of 45 kDa, and this material is
purified at least 100,000-fold (Table 1). The estimate of
protein values in the most purified fractions is indirect, as
mentioned in Materials and Methods. The low yield of
activity is due to poor recovery ofprotein during the removal
of NaDodSO4 rather than an irreversible denaturation of the
protein. The yield of protein in the 45-kDa peak is estimated
to be 70 ug, using 17.5 liters of CM as the starting material.
The factor is active at concentrations <10 ng/ml, and it
displays the ability to both induce AcCho synthesis and
reduce CA synthesis.
Protease Sensitivity. Weber (40) found that the activity of
the cholinergic factor in serum-containing CM was partially
decreased by treatment with a protease from Streptomyces
griseus, but that the preparation contained large amounts of
protease inhibitors, which precluded further analysis. The
activity in the Sephadex fraction from serum-free CM is
almost completely lost by treatment with trypsin (EC
3.4.21.4; Sigma, type III) [<10% remaining after incubation
with trypsin (2.5 pg/ml) at 37°C for 14 hr]. The trypsin was
inactivated with turkey egg white trypsin inhibitor after the
incubation (40). Thus, the biological activity appears to reside
in a protein.
Labeling the Protein. As shown in Fig. 1, silver staining
revealed no obvious band corresponding to the activity peak.
lodination of tyrosine residues by the lodo-Gen, chloramine-
T, and lactoperoxidase methods also failed to yield a distinct
band at 45 kDa. lodination of lysine residues by the
Bolton-Hunter method, however, did reveal a labeled band
at the 45-kDa region (Fig. 2). This protein comigrates with the
activity in two further analytical steps.
Two-Dimensional Gel Electrophoresis. Subjecting the 125I-
labeled Sephadex fraction to two-dimensional gel electro-
phoresis (nonequilibrium pH gradient electrophoresis is fol-
lowed by NaDodSO4/PAGE) reveals five distinct spots in the
45-kDa region (Fig. 3). When the 45-kDa region of the gel is
cut into small slices and assayed for both 125I and cholinergic
activity, results such as those shown in Fig. 4 are obtained.
The yield of biological activity is 60-80%o of that obtained in
one-dimensional gels. The comigration ofthe activity and the
labeled protein has been seen in all three experiments of this
type that have been done. Although each protein spot has
detectable activity, the relative intensity of these spots and
their relative biological activity vary in different experiments,
and the ratio of activity to "2-I varies considerably among the
spots, with the more acidic species having lower ratios. This
variation could be due to different degrees of iodination or to
different degrees of inactivation by iodination. lodination
itself, however, is not the cause of the charge differences
among the spots, because multiple spots of cholinergic
activity are also seen in unlabeled preparations (data not
shown). Whatever the reason, the fact that the activity peaks
kDa
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FIG. 1. NaDodSO4/PAGE of the Sephadex fraction. The Seph-
adex fraction was subjected to NaDodSO4/PAGE and the biological
activity eluted from each gel slice was tested. Illustrated on the top
part of the figure is a portion of the gel stained with silver by the
method of Merril et al. (53). There is no clear sharp band at the
45-kDa region corresponding to the activity peak at 45 kDa.
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FIG. 2. Labeling of 45-kDa protein. The Sephadex fraction was
either stained with silver (lane a), iodinated by the lodo-Gen method
(lane b), or by the Bolton-Hunter method (lane c). The 45-kDa area
where activity is located (arrow) is barely stained with silver (visible
only in the wet gel). It is not iodinated by the Iodo-Gen method,
which labels tyrosine residues, but it is heavily labeled by the
Bolton-Hunter iodination method, which primarily labels lysine
residues (51).
and the '25I-labeled spots line up precisely strongly suggests
that the labeled 45-kDa molecule is the cholinergic factor.
Deglycosylation of the Protein. When the purified 45-kDa
band is treated with endoglycosidase F, a series of six new
and distinct labeled bands appears, suggesting that there are
at least six glycosylation sites on the protein (Fig. 5).
Exhaustive deglycosylation converts all of the bands to the
species oflowest size, 22 kDa. This presumptive protein core
retains just as much biological activity as the 45-kDa band
incubated without endoglycosidase F (the increase in the
AcCho/CA ratio induced by the 22-kDa form is 1.3 times
higher than the increase induced by the 45-kDa form, using
equal amounts of "25I-labeled protein in two separate exper-
iments, and cholinergic activity was only found in the 22-kDa
band after exhaustive deglycosylation as in Fig. 5, lane e).
Thus, deglycosylation causes a shift in apparent molecular
size of 23 kDa, and the cholinergic activity again comigrates
with the labeled protein.
DISCUSSION
The evidence that the 125I-labeled 45-kDa protein is the
cholinergic factor is its comigration with the cholinergic
- NEPHGE
0
zSo
1-
I-I
ii
0
x
E0.
u.
0
Basic
160
5 10
Acidic
40 [7p
0
._.
20
Distance of migration, cm
FIG. 4. Cholinergic activity in two-dimensional gel electropho-
resis. The 45-kDa region of the two-dimensional gel similar to that
shown in Fig. 3 (except that the pH gradient was from 5.7 to 7.5) was
cut in 2.5-mm slices and the eluted fraction from each gel slice was
counted for 115I radioactivity and tested for biological activity. Each
of the activity peaks and the 1251 spots line up precisely, indicating
that the labeled 45-kDa molecule is the cholinergic factor.
activity after one- and two-dimensional gel electrophoresis
and after a large shift in apparent molecular size caused by
treatment with the enzyme endoglycosidase F. Final proof of
homogeneity requires N-terminal sequence analysis, and our
preliminary findings indicate that both the 45-kDa and 22-kDa
(deglycosylated by hydrogen fluoride) bands have a single
and identical N-terminal amino acid sequence (unpublished
data).
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FIG. 3. Two-dimensional gel analysis of the 251I-labeled Sepha-
dex fraction. The Sephadex fraction was iodinated by the
Bolton-Hunter method and subjected to nonequilibrium pH gradient
electrophoresis (NEPHGE) in the first dimension for 2000 V-h on a
gradient of pH 3.5-10. The material in the gel was then electropho-
resed in the second dimension on a 10%6 NaDodSO4/polyacrylamide
gel. The autoradiogram shows five discrete 125I-labeled spots at 45
kDa (arrowhead). No new spots were seen at 45 kDa when electro-
phoresis was carried out for 500 or 4000 VBhr. On the right is a
one-dimensional gel autoradiogram.
FIG. 5. Endoglycosidase F cleavage of the 45-kDa protein.
125I-labeled 45-kDa protein, purified from a two-dimensional gel (the
five 45-kDa spots combined) was treated for 16 hr at 370C with 0 unit
(lane a), 0.025 unit (lane b), 0.25 unit (lane c), 1.0 unit (lane d), and
10.0 units (lane e) of endoglycosidase F. The protein was analyzed
by NaDodSO4/10-15% PAGE, and autoradiogram of the dried gel is
shown. The exposure time was adjusted in order to visualize the faint
bands. Six discrete stages of cleavage are seen. When the protein is
cleaved exhaustively, virtually all of the label migrates at 22 kDa
(lane e).
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The cause of the charge microheterogeneity seen in two-
dimensional gel electrophoresis is unknown. It is unlikely
that carbohydrate contributes significantly to the generation
of five spots because preliminary results with neuraminidase-
and endoglycosidase F-treated samples also yield five 125I-
labeled spots. Iodination is also unlikely to be the major cause
because unlabeled material gives multiple spots as well.
Thus, either a different secondary modification, such as
phosphorylation or sulfation, or an artifactual modification
generated during the purification or analysis may be respon-
sible for the charge heterogeneity (60, 61).
The finding that full biological activity is retained after
exhaustive treatment with endoglycosidase F suggests that
the carbohydrate residues are not essential for the cholinergic
inducing activity of this protein. This contrasts with the result
of Weber (40), who found that the activity was destroyed by
mild periodate treatment. It is possible that periodate treat-
ment affected the protein core itself, or that the endogly-
cosidase F incubations did not completely remove the car-
bohydrate.
The loss of an apparent 23 kDa after deglycosylation
suggests the presence of considerable carbohydrate. How-
ever, the molecular weight of 45 kDa obtained for both the
denatured form (by NaDodSO4/PAGE) and the native form
(by Sephadex chromatography) could be an overestimate due
to a bulky hydrated structure caused by the presence of at
least six carbohydrate chains (62). It is of interest in this
regard that Weber has recently obtained an independent
estimate of 21 kDa for this or a very similar cholinergic factor
based on the sedimentation behavior ofthe activity in sucrose
gradients under native conditions (63).
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